Yunkang Group (HKSE:02325) Debt-to-Equity : 0.66 (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Yunkang Group Debt-to-Equity?

Yunkang Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$1,280.1 Mil. Yunkang Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$240.1 Mil. Yunkang Group's Total Stockholders Equity for the quarter that ended in Dec. 2023 was HK$2,310.2 Mil. Yunkang Group's debt to equity for the quarter that ended in Dec. 2023 was 0.66.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Yunkang Group's Debt-to-Equity or its related term are showing as below:

HKSE:02325' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.25 Med: 0.29 Max: 0.66
Current: 0.66

During the past 6 years, the highest Debt-to-Equity Ratio of Yunkang Group was 0.66. The lowest was 0.25. And the median was 0.29.

HKSE:02325's Debt-to-Equity is ranked worse than
74.09% of 193 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.23 vs HKSE:02325: 0.66

Yunkang Group Debt-to-Equity Historical Data

The historical data trend for Yunkang Group's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yunkang Group Debt-to-Equity Chart

Yunkang Group Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.27

0.47

0.25

0.31

0.66

Yunkang Group Semi-Annual Data
	Dec18	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial				0.25	0.21	0.31	0.44	0.66

Competitive Comparison of Yunkang Group's Debt-to-Equity

For the Diagnostics & Research subindustry, Yunkang Group's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Yunkang Group's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Yunkang Group's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Yunkang Group's Debt-to-Equity falls into.

Yunkang Group Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Yunkang Group's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1280.118	+	240.058)	/	2310.227
	=	0.66

Yunkang Group's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1280.118	+	240.058)	/	2310.227
	=	0.66

Yunkang Group (HKSE:02325) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Yunkang Group Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Yunkang Group's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Yunkang Group (HKSE:02325) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Yunkang Group Ltd (HKSE:02325) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 6 Lizhishan Road, Science City, Huangpu District, Guangzhou, CHN

Website

http://www.yunkanghealth.com

Yunkang Group Ltd is a medical operation service provider in China. The company has three major business lines namely covering diagnostic testing services for medical consortia, diagnostic outsourcing services, and non-medical institutions.

Executives

Huizekx Limited	2201 Interest of corporation controlled by you
Yk Development Limited	2101 Beneficial owner
Zhang Yong	2201 Interest of corporation controlled by you
Shanghai Pudong Development Bank Co., Ltd	2201 Interest of corporation controlled by you
Zhou Xinyu
Guang Zhou Da An Ji Yin Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you
Da An Guo Ji Ji Tuan You Xian Gong Si	2101 Beneficial owner
Guang Zhou Shi Da An Ji Yin Ke Ji You Xian Gong Si	2201 Interest of corporation controlled by you
Jin Jun Ying Limited	2201 Interest of corporation controlled by you
Mouduans Limited	2201 Interest of corporation controlled by you
Source Capital Rw Limited	2201 Interest of corporation controlled by you
Tongfuzc Limited	2201 Interest of corporation controlled by you
Wjjr Investment Limited	2201 Interest of corporation controlled by you

Yunkang Group (HKSE:02325) Headlines

No Headlines